Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies

被引：58

作者：

Gaullier, JM ^{[1
]}

Berven, G ^{[1
]}

Blankson, H ^{[1
]}

Gudmundsen, O ^{[1
]}

机构：

[1] Scandinavian Clin Res AS, N-2027 Kjeller, Norway

来源：

LIPIDS | 2002年 / 37卷 / 11期

关键词：

D O I：

10.1007/s11745-002-0995-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

CLA mixtures are now commercially available. They differ from each other with respect to their content of CLA isomers and their degree of purification, As a group of natural FA, CLA have been widely assumed to be safe. However, the suspected presence of both impurities and particular isomers might induce undesirable side effects. Despite this potent a health risk, only a few CLA preparations have been tested under rigorous conditions for clinical efficacy and safety, Based on tie limited results available, it is possible to suggest that preparations enriched in c9,t11 and t10,c12 isomers are preferable for human consumption compared to preparations containing four isomers, in terms both of safety and efficacy.

引用

页码：1019 / 1025

页数：7

共 58 条

[1]

Atkinson RL, 1999, ADVANCES IN CONJUGATED LINOLEIC ACID RESEARCH, VOL 1, P348

[2] Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid [J].